Over the past year there were no insider purchases at Fate Therapeutics Inc. Two insiders sold roughly $323,000 instead.
Selling on its own is common and often pre-planned (10b5-1 plans, taxes, diversification), so it matters more when it is unusually heavy or broad.
Looking at the quarterly pattern: 3 quarters in a row of net selling by insiders. Insiders bought in 0 of the last 7 full quarters. Big money check: 155 institutions held FATE as of Q2 2026, and more funds bought than sold.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Aug 5, 2026 | TAHL CINDY | Officer | Sell | 38,800 | $2.46 | $95K | SEC |
| Aug 5, 2026 | Valamehr Bahram | CEO | Sell | 43,947 | $2.46 | $108K | SEC |
| May 21, 2026 | TAHL CINDY | Officer | Sell | 25,590 | $1.88 | $48K | SEC |
| May 21, 2026 | Valamehr Bahram | CEO | Sell | 28,946 | $1.88 | $54K | SEC |
| Jan 12, 2026 | TAHL CINDY | Officer | Sell | 10,589 | $1.06 | $11K | SEC |
| Jan 12, 2026 | Valamehr Bahram | CEO | Sell | 5,190 | $1.07 | $6K | SEC |
| Aug 5, 2025 | TAHL CINDY | Officer | Sell | 9,037 | $1.06 | $10K | SEC |
| Aug 5, 2025 | Valamehr Bahram | CEO | Sell | 14,466 | $1.06 | $15K | SEC |
| Jan 13, 2025 | Bressi Jerome Charles | Officer | Sell | 5,980 | $1.55 | $9K | SEC |
| Jan 13, 2025 | TAHL CINDY | Officer | Sell | 5,654 | $1.55 | $9K | SEC |
| Jan 13, 2025 | Valamehr Bahram | CEO | Sell | 8,705 | $1.54 | $13K | SEC |
| Dec 26, 2024 | Green Jeremy | Director | Sell | 341,633 | $1.68 | $574K | SEC |
| Dec 26, 2024 | Green Jeremy | Director | Buy | 397,964 | $1.68 | $669K | SEC |
| Aug 7, 2024 | Xu Yuan | Director | Sell | 633 | $4.23 | $3K | SEC |
| Mar 5, 2024 | Dulac Edward J III | CFO | Sell | 2,447 | $7.77 | $19K | SEC |
In the last 12 months Fate Therapeutics Inc insiders made open-market purchases worth about $0 and sales worth about $323,000. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in FATE was filed on 2026-08-05.
155 investment managers reported holding FATE in SEC Form 13F filings for Q2 2026.
No congressional trades in FATE were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).